Short answer
REGENXBIO Inc. (RGNX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $108M (up 405.7% year over year) with net income of $23M.
Q2 2026 key financials · XBRL
- Revenue
- $108M
- +405.7% YoY · +1589.6% QoQ
- Net income
- $23M
- +132.0% YoY · +125.2% QoQ
- Operating margin
- 27.1%
- EPS (diluted)
- $0.44
- +131.9% YoY · +125.6% QoQ
Source: XBRL data from the REGENXBIO Inc. (RGNX) Q2 2026 10-Q on SEC EDGAR. USD.
REGENXBIO Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Risk factors section not provided; supplied text begins with Item 2 and contains no risk-factor disclosures
- Newly adopted Rule 10b5-1 plan: director David C. Stump, sale of 25,000 securities, adopted June 18, 2026
- Loan amendment: first amendment to REGENXBIO RS LLC loan agreement dated April 28, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other REGENXBIO Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.